arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

HALOZYME THERAPEUTICS, INC.

HALO
$103.05 ▲ +17.23 (+20.08%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Neutral
auto_awesome

Analytical Summary

HALOZYME THERAPEUTICS, INC. demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Debt to Equity which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $12.3B
Dividend Yield
Revenue Growth 37.6%
Op. Margin 33.6%
ROIC 14.5%
FCF / Share $5.38
Trailing P/E 39.0x
Price / Book 248.7x
FCF Yield 5.2%
Debt / Equity 43.89
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.40B
↑ +37.6%
Net Income Profit after all expenses
$316.89M
↓ -28.6%
Operating Margin Operating profit as % of sales
33.6%
↓ -38.2% 89th
FCF / Share Free cash flow per share
$5.38
↑ +45.6%
Long-Term Debt Long-term obligations
$2.14B
↑ +42.3%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
90
Financial Health
47
Cash Quality
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters